Tag Archives: SYRS

Cowen & Co. Thinks Syros Pharmaceuticals’ Stock is Going to Recover

In a report released today, Phil Nadeau from Cowen & Co. assigned a Buy rating to Syros Pharmaceuticals (NASDAQ: SYRS). The company’s shares opened today at $8.45, close to its 52-week low of $6.30. According to TipRanks.com, Nadeau is a

Syros Pharmaceuticals Initiated with a Hold at Roth Capital

Roth Capital analyst Jotin Marango initiated coverage with a Hold rating on Syros Pharmaceuticals (NASDAQ: SYRS) yesterday and set a price target of $16. The company’s shares closed yesterday at $17.06. According to TipRanks.com, Marango is ranked #3353 out of

Analysts’ Top Healthcare Picks: SYRS, AMGN

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Syros Pharmaceuticals (NASDAQ: SYRS), Amgen Inc (NASDAQ: AMGN) and Prothena Corp (NASDAQ: PRTA) with bullish sentiments. Syros Pharmaceuticals (NASDAQ: SYRS) JMP Securities

Oppenheimer Reaffirms Their Buy Rating on Syros Pharmaceuticals

Oppenheimer analyst Leah R. Cann reiterated a Buy rating on Syros Pharmaceuticals (NASDAQ: SYRS) today and set a price target of $28. The company’s shares closed on Friday at $20.17. R. Cann said: “Syros announced today that FDA has granted

Cowen & Co. Keeps Their Buy Rating on Syros Pharmaceuticals

Cowen & Co. analyst Phil Nadeau reiterated a Buy rating on Syros Pharmaceuticals (NASDAQ: SYRS) yesterday. The company’s shares closed yesterday at $22.84, close to its 52-week high of $24.38. According to TipRanks.com, Nadeau is a 5-star analyst with an

Oppenheimer Remains a Buy on Syros Pharmaceuticals

Oppenheimer analyst Leah R. Cann reiterated a Buy rating on Syros Pharmaceuticals (NASDAQ: SYRS) today and set a price target of $28. The company’s shares opened today at $18.77, close to its 52-week high of $19.22. R. Cann wrote: “Syros